Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNR NASDAQ:CDNA NASDAQ:FLGT NASDAQ:GTH NASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNRBurning Rock Biotech$8.26-2.8%$7.23$2.18▼$11.12$88.82M0.9131,302 shs13,046 shsCDNACareDx$14.36+1.3%$13.64$10.96▼$32.97$764.38M2.281.20 million shs1.11 million shsFLGTFulgent Genetics$21.84-0.5%$20.37$14.57▼$23.56$667.15M0.82340,689 shs78,097 shsGTHGenetron$4.03$3.98$2.08▼$4.05$127.27M0.5151,662 shs412,603 shsVCYTVeracyte$32.03-0.8%$27.94$22.61▼$47.32$2.52B2.071.14 million shs374,674 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNRBurning Rock Biotech-2.53%-9.10%+13.50%+133.95%+137.82%CDNACareDx+1.14%+5.43%+19.76%-25.49%-52.30%FLGTFulgent Genetics-0.18%-1.70%+3.20%+8.08%-0.72%GTHGenetron0.00%0.00%0.00%0.00%-0.12%VCYTVeracyte+1.29%+0.91%+6.82%+20.36%-4.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNRBurning Rock Biotech$8.26-2.8%$7.23$2.18▼$11.12$88.82M0.9131,302 shs13,046 shsCDNACareDx$14.36+1.3%$13.64$10.96▼$32.97$764.38M2.281.20 million shs1.11 million shsFLGTFulgent Genetics$21.84-0.5%$20.37$14.57▼$23.56$667.15M0.82340,689 shs78,097 shsGTHGenetron$4.03$3.98$2.08▼$4.05$127.27M0.5151,662 shs412,603 shsVCYTVeracyte$32.03-0.8%$27.94$22.61▼$47.32$2.52B2.071.14 million shs374,674 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNRBurning Rock Biotech-2.53%-9.10%+13.50%+133.95%+137.82%CDNACareDx+1.14%+5.43%+19.76%-25.49%-52.30%FLGTFulgent Genetics-0.18%-1.70%+3.20%+8.08%-0.72%GTHGenetron0.00%0.00%0.00%0.00%-0.12%VCYTVeracyte+1.29%+0.91%+6.82%+20.36%-4.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNRBurning Rock Biotech 0.00N/AN/AN/ACDNACareDx 2.57Moderate Buy$25.5077.55% UpsideFLGTFulgent Genetics 2.67Moderate Buy$25.3316.01% UpsideGTHGenetron 0.00N/AN/AN/AVCYTVeracyte 2.70Moderate Buy$40.9027.70% UpsideCurrent Analyst Ratings BreakdownLatest BNR, VCYT, FLGT, CDNA, and GTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025CDNACareDxBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.008/26/2025CDNACareDxWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform8/8/2025VCYTVeracyteMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetUnderweight$28.008/8/2025CDNACareDxWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$19.00 ➝ $14.008/5/2025FLGTFulgent GeneticsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$20.00 ➝ $30.008/4/2025FLGTFulgent GeneticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral$23.00 ➝ $21.007/18/2025CDNACareDxCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $26.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNRBurning Rock Biotech$70.67M1.26N/AN/A$7.39 per share1.12CDNACareDx$333.79M2.29$1.39 per share10.31$7.06 per share2.03FLGTFulgent Genetics$283.47M2.36N/AN/A$36.92 per share0.59GTHGenetron$94.34M1.35N/AN/A$2.63 per share1.53VCYTVeracyte$445.76M5.65$1.04 per share30.74$15.17 per share2.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNRBurning Rock Biotech-$47.49M-$1.90N/A∞N/A-26.04%-23.61%-15.73%N/ACDNACareDx$52.55M$1.0214.08N/AN/A17.97%18.03%12.88%11/3/2025 (Estimated)FLGTFulgent Genetics-$42.71M-$1.66N/AN/AN/A-16.83%-2.26%-2.10%11/14/2025 (Estimated)GTHGenetron-$117.21MN/A0.00∞N/AN/AN/AN/AN/AVCYTVeracyte$24.14M$0.3396.9644.48N/A5.50%6.07%5.53%11/5/2025 (Estimated)Latest BNR, VCYT, FLGT, CDNA, and GTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/8/2025Q2 2025BNRBurning Rock BiotechN/A-$0.15N/A-$0.15N/A$20.74 million8/6/2025Q2 2025CDNACareDx$0.12-$0.16-$0.28-$0.16$90.72 million$90.51 million8/1/2025Q2 2025FLGTFulgent Genetics-$0.23$0.07+$0.30-$0.62$76.21 million$81.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNRBurning Rock BiotechN/AN/AN/AN/AN/ACDNACareDxN/AN/AN/AN/AN/AFLGTFulgent GeneticsN/AN/AN/AN/AN/AGTHGenetronN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNRBurning Rock BiotechN/A3.222.97CDNACareDxN/A3.303.00FLGTFulgent GeneticsN/A6.016.01GTHGenetronN/AN/AN/AVCYTVeracyteN/A5.435.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNRBurning Rock Biotech30.03%CDNACareDxN/AFLGTFulgent Genetics48.06%GTHGenetron10.74%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipBNRBurning Rock Biotech30.30%CDNACareDx4.40%FLGTFulgent Genetics33.11%GTHGenetronN/AVCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNRBurning Rock Biotech1,39010.76 million7.50 millionNot OptionableCDNACareDx74053.23 million50.89 millionOptionableFLGTFulgent Genetics1,31330.61 million20.47 millionOptionableGTHGenetron99331.62 millionN/ANot OptionableVCYTVeracyte79078.67 million77.57 millionOptionableBNR, VCYT, FLGT, CDNA, and GTH HeadlinesRecent News About These CompaniesAQR Capital Management LLC Lowers Stock Position in Veracyte, Inc. $VCYTSeptember 15 at 3:12 AM | marketbeat.comVeracyte, Inc. $VCYT Stake Trimmed by Great Lakes Advisors LLCSeptember 13, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) CEO Sells 7,667 SharesSeptember 10, 2025 | marketbeat.comVeracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual MeetingSeptember 10, 2025 | finance.yahoo.comVeracyte, Inc. (VCYT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comMarc Stapley Sells 7,667 Shares of Veracyte (NASDAQ:VCYT) StockSeptember 9, 2025 | insidertrades.comVeracyte, Inc. (NASDAQ:VCYT) Receives $40.90 Average Target Price from AnalystsSeptember 9, 2025 | americanbankingnews.comVeracyte, Inc. $VCYT Stake Lifted by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comBridgeway Capital Management LLC Sells 41,300 Shares of Veracyte, Inc. $VCYTSeptember 8, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 8, 2025 | marketbeat.comRaymond James Financial Inc. Purchases 172,010 Shares of Veracyte, Inc. $VCYTSeptember 6, 2025 | marketbeat.comPDT Partners LLC Sells 27,566 Shares of Veracyte, Inc. $VCYTSeptember 5, 2025 | marketbeat.comMagnetar Financial LLC Invests $651,000 in Veracyte, Inc. $VCYTSeptember 3, 2025 | marketbeat.comTrexquant Investment LP Sells 10,790 Shares of Veracyte, Inc. $VCYTSeptember 3, 2025 | marketbeat.comHsbc Holdings PLC Buys 10,618 Shares of Veracyte, Inc. $VCYTSeptember 2, 2025 | marketbeat.comRafferty Asset Management LLC Has $3.29 Million Stock Position in Veracyte, Inc. $VCYTSeptember 1, 2025 | marketbeat.comNorthern Trust Corp Trims Stake in Veracyte, Inc. $VCYTSeptember 1, 2025 | marketbeat.comDriehaus Capital Management LLC Purchases 167,604 Shares of Veracyte, Inc. $VCYTAugust 31, 2025 | marketbeat.comRussell Investments Group Ltd. Sells 28,644 Shares of Veracyte, Inc. $VCYTAugust 31, 2025 | marketbeat.comNext Century Growth Investors LLC Lowers Stake in Veracyte, Inc. $VCYTAugust 30, 2025 | marketbeat.comVeracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare ConferenceAugust 29, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBNR, VCYT, FLGT, CDNA, and GTH Company DescriptionsBurning Rock Biotech NASDAQ:BNR$8.26 -0.24 (-2.77%) As of 03:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.CareDx NASDAQ:CDNA$14.36 +0.18 (+1.28%) As of 03:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Fulgent Genetics NASDAQ:FLGT$21.84 -0.10 (-0.47%) As of 03:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Genetron NASDAQ:GTHGenetron Holdings Limited, a precision oncology platform company, focuses on cancer management by utilizing technologies in molecular biology and data science in the People's Republic of China. It offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. The company also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. Genetron Holdings Limited was founded in 2013 and is headquartered in Beijing, the People's Republic of China.Veracyte NASDAQ:VCYT$32.03 -0.25 (-0.78%) As of 03:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
